ClinicalTrials.gg
CompletedNCT00441090Updated Mar 7, 2018Results posted

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

A Phase 2 interventional study of Placebo and Avatrombopag tablets in Chronic Idiopathic Thrombocytopenic Purpura and Purpura, Thrombocytopenic, Idiopathic, sponsored by Eisai Inc.. Completed at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-07.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. avatrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
5th of 16
64 · median 53
Started
2007
with 1 other
Phase 2
4 of 16
2 open now
Registered
1st of 16
by date
Lead sponsor
7 of 16
Eisai Inc.

Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 5th largest by enrollment, is one of 2 that started in 2007, is one of 4 in phase 2, and was the 1st registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About avatrombopag

avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy, safety and tolerability, of AKR-501 (avatrombopag) tablets, as compared to placebo, in the treatment of participants with chronic Idiopathic Thrombocytopenic Purpura (ITP).

Read the detailed description

This is a Phase 2, multi-center, double-blind, randomized, placebo-controlled, dose-ranging, parallel-group study. The pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/PD) relationship of avatrombopag will also be studied. Approximately 65 eligible participants will be randomized in a 3:3:3:3:1 ratio in a double-blinded fashion into one of five parallel treatment groups to receive daily doses of either avatrombopag 2.5, 5, 10 or 20 mg or placebo for 28 days, respectively. Each avatrombopag dosing group will consist of 15 participants while the placebo group will consist of 5 participants. All study participants will be evaluated weekly (Days 3, 5, 7, 14, 21 and 28) for safety, efficacy, and (Days 7, 14, 21, and 28) avatrombopag PK while receiving study treatment with a final assessment for safety and effectiveness to be done 2 weeks after the last study dose (Day 42).

At the completion of Visit Day 28±1, participants who complete 28±1 days of study dosing will be assessed for eligibility to enroll into the rollover Study 501-CL-004 (NCT00625443) based on this visit.

03

Conditions studied

  • Chronic Idiopathic Thrombocytopenic Purpura
  • Purpura, Thrombocytopenic, Idiopathic

Keywords

  • Chronic Idiopathic Thrombocytopenic Purpura
  • Idiopathic Thrombocytopenic Purpura
  • ITP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women ≥ 18 years of age.
  2. Confirmed diagnosis of ITP according to American Society of Hematology (ASH) Guidelines ≥ 3 months prior to Day 1.
  3. If ≥ 60 years old, must have had either a bone marrow consistent with ITP within past 3 years or a good response ( count > 100,000/mm\^3) to a previous ITP treatment.
  4. Are or relapsed after at least one prior ITP therapy (patients who are refractory and failed to achieve a platelet count ≥ 50,000/mm\^3 despite or ≥ 30,000/mm\^3 to other prior ITP therapies, such as splenectomy, danazol, or drugs. For patients who are relapsed, the platelet counts must be below 50,000/mm\^3 if using steroids or 30,000/mm\^3 if not prescribed steroids.)
  5. Patients receiving maintenance corticosteroids may be enrolled, as long as the corticosteroids have been administered at a stable dose (same milligram amount ± 10%) for ≥ 2 weeks prior to Screening Visit A and the investigator does not foresee the need to change the steroid dose during study participation. Patients should remain on this stable corticosteroid dose during study participation.
  6. Patients receiving stable dosages of cyclosporine A, mycophenolate mofetil, azathioprine or danazol may also be enrolled. The dosages of all these medications must be stable for at least 3 months prior to AKR-501 administration.
  7. Platelet count:

    • Patients not receiving steroids (no steroid treatment for > 2 weeks prior to the Screening Visit A): platelets \< 30,000/mm\^3 at Screening Visit A and within 96 hours prior to Day 1 (Screening Visit B)
    • Patients receiving steroids: platelets \< 50,000/mm\^3 at Screening Visit A and within 96 hours prior to Day 1 (Screening Visit B).
  8. Women of must have a negative pregnancy test at Screening Visit A and Screening Visit B. (Childbearing potential is defined as any woman who has not been surgically sterilized and is premenopausal or peri-menopausal i.e., any menstrual flow within 12 months of Screening Visit A).
  9. Women of child-bearing potential and all men must agree to practice a medically approved form of (one of the following must be used: condoms (male or female) with a spermicidal agent, diaphragm, or cervical cap with a spermicidal agent, IUD, hormonal contraception, abstinence).
  10. Willing and able to provide written before any study-related procedure.

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant and/or lactating.
  2. Splenectomy procedure performed 4 weeks prior to AKR-501 administration.
  3. Use of the following drugs or treatments prior to Day 1:

    • Within 3 months - Rituximab;
    • Within 2 weeks - Aspirin or Aspirin-containing compounds, Salicylates, Anticoagulants, clopidogrel, ticlopidine, Rh0(D) Immune Globulin (WinRho®), or intravenous immunoglobulin (IVIG).
  4. Participation in a clinical trial involving any agent within 4 weeks of Day 1.
  5. Exposure to eltrombopag or AMG -531.
  6. Significant medical conditions or diseases as determined by the Investigator (e.g., clinically active systemic lupus erythematosus; known or suspected infection; acute hepatitis or clinically active chronic hepatitis; lymphoproliferative disease; congestive heart failure).
  7. History of cardiovascular disease (e.g., angina, unstable angina, myocardial infraction, coronary artery stent placement, angioplasty, coronary artery bypass grafting).
  8. History of thromboembolic disease (e.g., [TIA], stroke [CVA], pulmonary embolism [PE]).
  9. History of deep venous thrombosis (DVT).
  10. History of lupus anticoagulant or anticardiolipin antibody syndrome or positive anti b2 glycoprotein antibody.
  11. History of any medical condition where systemic anticoagulation was required for more than 6 months.
  12. Laboratory abnormalities:

    • \< 12.5 g/dL for men and \< 11.5 g/dL for women. If anemia is clearly related to ITP, for example excessive blood loss, then that patient may be enrolled without the need for a waiver after discussion with the Sponsor's medical monitor
    • White blood cell count (WBC) \< lower limit of normal
    • (ANC) \< 1000/mm\^3
    • (PT) > 1.25 x
    • Partial thromboplastin time (PTT) > 1.25 x upper limit of normal
    • Total > 3 x upper normal limit
    • (ALT) > 3 x upper normal limit
    • Aspartate transaminase (AST) > 3 x upper normal limit
    • Creatinine > 1.5x upper normal limit
    • Blood urea nitrogen (BUN) > 1.5 x upper normal limit
    • HIV positive
    • IgM HAV positive, surface antigen (HBsAg) or antibody (HCV) positive.
  13. History of, or current alcohol or drug abuse likely to interfere with ability to comply with protocol.

    requirements or give , as determined by the Investigator.

  14. History of, or current psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent, as determined by the Investigator.
  15. Currently taking any of the following medications: Rituximab, Aspirin or Aspirin-containing compounds, Salicylates, Anticoagulants, clopidogrel, ticlopidine, Rh0(D) Immune Globulin (WinRho®), or intravenous immunoglobulin (IVIG).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Avatrombopag tablets

    2.5, 5, 10 or 20 mg tablets 1 tablet taken orally once daily for 28 days

    Drug: Avatrombopag tablets

  • Placebo comparator
    Placebo tablet

    2.5, 5, 10, or 20 mg tablets 1 tablet taken orally once daily for 28 days

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.

  • Avatrombopag tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.

    Also known as: AKR-501, E5501, YM477

06

What researchers measure

Primary outcomes

  1. Responder Rate (RR) to Avatrombopag on Day 28

    Platelet counts were measured from the participant's blood, which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Day 28. The RR was defined as the percentage of participants with a Day 1 platelet count of less than 30,000/milliliter (mL) who reached a platelet count of greater than or equal to 50,000/mL on Day 28 of study medication, together with the percentage of participants using steroids who had a Day 1 platelet count greater than or equal to 30,000/mL but less than 50,000/mL who reached a platelet count of greater than or equal to 20,000/mL higher than their Day 1 platelet count on Day 28 of study medication. The RR was summarized by treatment group using the method of last observation carried forward (LOCF).

    Time frame: Day-4 to Day 1, Baseline, Day 28

Secondary outcomes

  1. Change in Platelet Count From Baseline

    Platelet counts were measured from the participant's, blood which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28. The unit of measure was "K/mm\^3", where "K = platelets x 1000 = platelets x 10\^3" and "mm\^3 = cubic milliliter= microliter".

    Time frame: Day -4 to Day 1, Baseline, Day 7, Day 14, Day 21, Day 28

  2. Responder Rate to Avatrombopag by Visit

    Platelet counts were measured from the participant's blood, which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, and 21. The RR was summarized by treatment group using the method of LOCF. Day 28 was not included with this data because it was reported as a primary outcome measure.

    Time frame: Day -4 to Day 1, Baseline, Day 7, Day 14, and Day 21

  3. Percentage of Participants With Platelet Counts Greater Than or Equal to 50,000/mL by Visit

    Platelet counts were measured from the participant's blood, which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28.

    Time frame: Day -4 to Day 1, Baseline, Day 7, Day 14, Day 21, and Day 28

  4. Percentage of Participants With Platelet Counts Greater Than or Equal to 100,000/mL by Visit

    Platelet counts were measured from the participant's, blood which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28.

    Time frame: Day -4 to Day 1, Baseline, Day 7, Day 14, Day 21, and Day 28

  5. Percentage of Participants Whose Platelet Counts Doubled From Baseline by Visit

    Platelet counts were measured from the participant's, blood which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28.

    Time frame: Day -4 to Day 1, Baseline, Day 7, Day 14, Day 21, and Day 28

Other outcomes

  1. To Evaluate the Pharmacokinetics (PK) and the Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship of Avatrombopag in Patients With ITP.

    Given the sparse PK sampling in this study, PK data from outside studies, which includes healthy subjects, were included to assist in PK model development. As a result this data was not reported with these study results.

    Time frame: Days 7, 14, 21 and 28

07

Results

Posted Jan 4, 2018

Participant flow

Participant flow — Overall Study
Milestone2.5 mg Avatrombopag5.0 mg Avatrombopag10.0 mg Avatrombopag20.0 mg AvatrombopagPlacebo
Started151514155
Completed131412135
Not completed21220
Withdrew: Adverse event01100
Withdrew: Platelet increase;more than 500,000 mm^300020
Withdrew: Withdrawal by subject10100
Withdrew: Lack of efficacy10000

Outcome measures

PrimaryResponder Rate (RR) to Avatrombopag on Day 28

Platelet counts were measured from the participant's blood, which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Day 28. The RR was defined as the percentage of participants with a Day 1 platelet count of less than 30,000/milliliter (mL) who reached a platelet count of greater than or equal to 50,000/mL on Day 28 of study medication, together with the percentage of participants using steroids who had a Day 1 platelet count greater than or equal to 30,000/mL but less than 50,000/mL who reached a platelet count of greater than or equal to 20,000/mL higher than their Day 1 platelet count on Day 28 of study medication. The RR was summarized by treatment group using the method of last observation carried forward (LOCF).

Time frame:
Day-4 to Day 1, Baseline, Day 28
Reported as:
Number · Percentage of participants
Responder Rate (RR) to Avatrombopag on Day 28
Percentage of participants2.5 mg Avatrombopag5.0 mg Avatrombopag10.0 mg Avatrombopag20.0 mg AvatrombopagPlacebo
Responder Rate (RR) to Avatrombopag on Day 2813.353.350.080.00
SecondaryChange in Platelet Count From Baseline

Platelet counts were measured from the participant's, blood which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28. The unit of measure was "K/mm\^3", where "K = platelets x 1000 = platelets x 10\^3" and "mm\^3 = cubic milliliter= microliter".

Time frame:
Day -4 to Day 1, Baseline, Day 7, Day 14, Day 21, Day 28
Reported as:
Mean · platelets x 10^3/mm^3
Change in Platelet Count From Baseline
platelets x 10^3/mm^32.5 mg Avatrombopag5.0 mg Avatrombopag10.0 mg Avatrombopag20.0 mg AvatrombopagPlacebo
Day 713.6 ± 22.3746.7 ± 55.2268.3 ± 81.23168.8 ± 114.595.0 ± 9.54
Day 1412.5 ± 22.6457.5 ± 74.72103.1 ± 119.55332.4 ± 278.96-1.4 ± 4.16
Day 217.5 ± 18.3847.1 ± 54.5480.6 ± 129.98261.3 ± 278.178.4 ± 13.72
Day 287.3 ± 23.7443.7 ± 50.3581.0 ± 124.55200.2 ± 292.36-1.8 ± 7.73
SecondaryResponder Rate to Avatrombopag by Visit

Platelet counts were measured from the participant's blood, which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, and 21. The RR was summarized by treatment group using the method of LOCF. Day 28 was not included with this data because it was reported as a primary outcome measure.

Time frame:
Day -4 to Day 1, Baseline, Day 7, Day 14, and Day 21
Reported as:
Number · Percentage of participants
Responder Rate to Avatrombopag by Visit
Percentage of participants2.5 mg Avatrombopag5.0 mg Avatrombopag10.0 mg Avatrombopag20.0 mg AvatrombopagPlacebo
Day 76.766.764.393.30
Day 1420.060.078.693.30
Day 2113.360.050.086.70
SecondaryPercentage of Participants With Platelet Counts Greater Than or Equal to 50,000/mL by Visit

Platelet counts were measured from the participant's blood, which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28.

Time frame:
Day -4 to Day 1, Baseline, Day 7, Day 14, Day 21, and Day 28
Reported as:
Number · Percentage of participants
Percentage of Participants With Platelet Counts Greater Than or Equal to 50,000/mL by Visit
Percentage of participants2.5 mg Avatrombopag5.0 mg Avatrombopag10.0 mg Avatrombopag20.0 mg AvatrombopagPlacebo
Day 76.766.764.393.30
Day 1420.060.078.693.30
Day 2113.360.050.086.720.0
Day 2813.353.350.080.00
SecondaryPercentage of Participants With Platelet Counts Greater Than or Equal to 100,000/mL by Visit

Platelet counts were measured from the participant's, blood which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28.

Time frame:
Day -4 to Day 1, Baseline, Day 7, Day 14, Day 21, and Day 28
Reported as:
Number · Percentage of participants
Percentage of Participants With Platelet Counts Greater Than or Equal to 100,000/mL by Visit
Percentage of participants2.5 mg Avatrombopag5.0 mg Avatrombopag10.0 mg Avatrombopag20.0 mg AvatrombopagPlacebo
Day 76.720.028.680.00
Day 14026.742.986.70
Day 21020.021.473.30
Day 286.733.328.653.30
SecondaryPercentage of Participants Whose Platelet Counts Doubled From Baseline by Visit

Platelet counts were measured from the participant's, blood which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28.

Time frame:
Day -4 to Day 1, Baseline, Day 7, Day 14, Day 21, and Day 28
Reported as:
Number · Percentage of participants
Percentage of Participants Whose Platelet Counts Doubled From Baseline by Visit
Percentage of participants2.5 mg Avatrombopag5.0 mg Avatrombopag10.0 mg Avatrombopag20.0 mg AvatrombopagPlacebo
Day 733.360.078.693.320.0
Day 1426.760.071.493.30
Day 216.760.064.386.720.0
Day 2813.353.357.186.720.0
Other pre-specifiedTo Evaluate the Pharmacokinetics (PK) and the Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship of Avatrombopag in Patients With ITP.

Given the sparse PK sampling in this study, PK data from outside studies, which includes healthy subjects, were included to assist in PK model development. As a result this data was not reported with these study results.

Time frame:
Days 7, 14, 21 and 28

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events (AEs) and serious adverse events (SAEs) were collected from first dose of study drug until last follow-up visit, or 30 days following discontinuation of study drug, whichever occurred later, or approximately 91 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2.5 mg Avatrombopag—2/15 (13.3%)12/15 (80%)
5.0 mg Avatrombopag—0/15 (0%)13/15 (86.7%)
10.0 mg Avatrombopag—1/14 (7.1%)11/14 (78.6%)
20.0 mg Avatrombopag—0/15 (0%)14/15 (93.3%)
Placebo—0/5 (0%)4/5 (80%)
Most frequent serious events
Most frequent serious events
Event2.5 mg Avatrombopag5.0 mg Avatrombopag10.0 mg Avatrombopag20.0 mg AvatrombopagPlacebo
Myocardial infarctionCardiac disorders0/150/151/140/150/5
Renal artery occlusionEye disorders0/150/151/140/150/5
PneumoniaInfections and infestations0/150/151/140/150/5
Transient ischaemic attackNervous system disorders0/150/151/140/150/5
ThrombocytopeniaBlood and lymphatic system disorders1/150/150/140/150/5
Gastric haemorrhagicGastrointestinal disorders1/150/150/140/150/5
Most frequent other events
Showing 10 of 101
Most frequent other events
Event2.5 mg Avatrombopag5.0 mg Avatrombopag10.0 mg Avatrombopag20.0 mg AvatrombopagPlacebo
FatigueGeneral disorders2/154/154/142/151/5
Platelet count increasedInvestigations0/150/150/144/150/5
HeadacheNervous system disorders4/153/151/144/151/5
EpistaxisRespiratory, thoracic and mediastinal disorders4/152/151/142/151/5
EcchymosisSkin and subcutaneous tissue disorders0/150/153/140/150/5
AnaemiaBlood and lymphatic system disorders0/150/150/141/151/5
Auricular swellingEar and labyrinth disorders0/150/150/140/151/5
DyspepsiaGastrointestinal disorders1/150/151/140/151/5
HaematocheziaGastrointestinal disorders0/151/150/140/151/5
Bowel sounds abnormalGastrointestinal disorders0/150/150/140/151/5

Baseline characteristics

Randomized (Intent-to-Treat) population included all participants who were randomly assigned to treatment.

Age, Continuous
Age, Continuous(Years)2.5 mg Avatrombopag5.0 mg Avatrombopag10.0 mg Avatrombopag20.0 mg AvatrombopagPlaceboTotal
Mean52.9 ± 17.8455.6 ± 18.0357.5 ± 17.8847.9 ± 16.5439.6 ± 20.6352.3 ± 17.81
Sex: Female, Male
Sex: Female, Male(Participants)2.5 mg Avatrombopag5.0 mg Avatrombopag10.0 mg Avatrombopag20.0 mg AvatrombopagPlaceboTotal
Female99811340
Male6664224
08

Study locations

25 sites
  • Pacific Cancer Medical Center, Inc
    Anaheim, California 92801, United States
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • Bay Area Cancer Research Group, LLC
    Concord, California, United States
  • Pacific Coast Hematology/Oncology Medical Group Inc.
    Fountain Valley, California 92708, United States
  • University of California Irvine Cancer Center
    Orange, California 92618, United States
  • Davis, Posteraro and Wasser, MDs, LLP
    Manchester, Connecticut 06105, United States
  • Georgetown University
    Washington, District of Columbia, United States
  • Florida Cancer Institute
    New Port Richey, Florida 34655, United States
  • Columbus Clinic, PC
    Columbus, Georgia 31901, United States
  • John H. Stroger, Jr. Hospital of Cook County, Div. of Hematology and Oncology
    Chicago, Illinois 60612, United States
  • Comprehensive Bleeding Disorders Center
    Peoria, Illinois 61614, United States
  • Cancer Care Center, Inc.
    New Albany, Indiana 47150, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Capitol Comprehensive Cancer Care Clinic
    Jefferson City, Missouri 65109, United States
  • Kansas City Cancer Center, LLC
    Kansas City, Missouri 64131, United States
  • UMDNJ - Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • New York Presbyterian Hospital, Weill Medical College of Cornell University
    New York, New York 10032, United States
  • Emerywood Oncology and Hematology
    High Point, North Carolina 27262, United States
  • Mid Ohio Oncology/Hematology, Inc., dba The Mark H. Zangmeister Center
    Columbus, Ohio 43219, United States
  • UPENN
    Philadelphia, Pennsylvania 19104, United States
  • Western Pennsylvania Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Cancer Centers of the Carolina
    Greenville, South Carolina 29605, United States
  • Puget Sound Blood Center
    Seattle, Washington 98014, United States
09

References and documents

Publications

  • Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. doi: 10.1182/blood-2013-07-514398. Epub 2014 May 6. PubMed 24802775 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Jan 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2018, 9 years after primary completion. A results delay was requested in May 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2007
First posted
Feb 28, 2007
Start
Feb 2007
Primary completionActual
Jan 2009
CompletionActual
Jun 2009
Results delay requested
May 21, 2013
Results first posted
Jan 4, 2018
Last update
Mar 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00441090
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Feb 28, 2007
Start date
Feb 2007
Primary completion
Jan 2009
Completion
Jun 2009
Results posted
Jan 4, 2018
Last update
Mar 7, 2018

Study contacts

Pei-Ran Ho, MD
study director · Eisai Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avatrombopag

Start the discussion